Skip to main content
. 2003 Jan;10(1):88–94. doi: 10.1128/CDLI.10.1.88-94.2003

TABLE 3.

Antibody response among Individuals with Pulmonary Tb and Controls

Subject Titer
Predominant IgG subclass % of maximal inhibition by:
IgM IgG MAb 5c11 MAb 9d8
Pulmonary TB patients
    A 1:150 1:109,350 IgG2 NIa NI
    B 1:150 1:36,150 IgG1 70 79
    C 1:50 1:109,350 IgG2 65 44
    D 1:150 1:36,150 IgG1 46 NI
    E 1:450 1:109,350 IgG2 77 81
    F 1:1,350 1:1,350 IgG2 56 NI
    G 1:450 1:109,350 IgG2 78 NI
    H 1:50 1:12,150 IgG2 56 NI
    I 1:1,350 1:12,150 NRb 57 NI
    J 1:50 1:450 NR 40 NI
    K NR 1:109,350 IgG2 NI NI
    L 1:4,050 1:12,150 IgG2 58 NI
    M 1:150 1:4,050 IgG2 52 NI
    N 1:50 1:450 NR NI NI
    O 1:150 1:12,150 IgG2 57 NI
    P 1:150 1:36,150 IgG2 63 NI
    Q 1:150 1:36,150 IgG2 76 NI
    R 1:1,350 1:36,150 IgG2 NI NI
    S 1:150 1:12,150 IgG2 NI NI
    T 1:150 1:12,150 IgG2 NI NI
Controls
    1 1:50 1:1,350 IgG2 68 NI
    2 1:1,350 1:4,050 NR 67 NI
    3 NR 1:12,150 IgG2 33 NI
    4 NR 1:12,150 IgG2 59 NI
    5 1:50 1:1,350 NR 44 NI
    6 1:1,350 1:450 IgG2 51 NI
    7 1:50 1:4,050 NR 58 NI
    8 1:50 1:1,350 NR 59 NI
    9 1:50 NR NR NI NI
    10 1:50 1:1,350 IgG2 67 NI
    11 1:150 1:4,050 NR NI NI
    12 1:450 1:36,150 IgG2 75 NI
    13 NR 1:1,350 IgG2 NI NI
    14 NR 1:450 IgG4 77 NI
    15 1:50 1:4,050 IgG2 NI NI
    16 1:150 1:450 IgG2 71 NI
    17 1:50 1:4,050 IgG2 52 NI
a

NI, no inhibition.

b

NR, nonreactive.

HHS Vulnerability Disclosure